Hillhouse-backed GenScript ProBio set to raise $224m from Legend Capital, others
The Series C deal, upon closing, would dilute GenScript Biotech's stake in Probio Cayman.
Stay updated with breaking news from Genscript Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Series C deal, upon closing, would dilute GenScript Biotech's stake in Probio Cayman.
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January.
/PRNewswire/ -- GenScript USA Inc., the world's leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP)...
/PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is partnering with Allozymes, a...
Drug Discovery Outsourcing Market to Reach ~US$ 12.7 Bn by the end of 2030 | Say’s TMR